(VIANEWS) – Gladstone Investment Corporation (GAIN), Medallion Financial Corp. (MFIN), Neurocrine Biosciences (NBIX) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Gladstone Investment Corporation (GAIN)
64.3% sales growth and 16.68% return on equity
Gladstone Investment Corporation is business development company, specializes in lower middle market, mature stage, buyouts; refinancing existing debt; senior debt securities such as senior loans, senior term loans, lines of credit, and senior notes; senior subordinated debt securities such as senior subordinated loans and senior subordinated notes; junior subordinated debt securities such as subordinated notes and mezzanine loans; limited liability company interests, and warrants or options. The fund does not invest in start-ups. The fund seeks to invest in manufacturing, consumer products and business/consumer services sector. It seeks to invest in small and mid-sized companies based in the United States. The fund prefers to make debt investments between $5 million and $30 million and equity investments between $10 million and $40 million in companies. The fund seeks to invest in companies with revenue between $20 million and $100 million. The fund invests in companies with EBITDA from $3 million to $20 million. It seeks minority equity ownership and prefers to hold a board seat in its portfolio companies. It also prefers to take majority stake in its portfolio companies. The fund typically holds the investments for seven years and exits via sale or recapitalization, initial public offering, or sale to third party.
Earnings Per Share
As for profitability, Gladstone Investment Corporation has a trailing twelve months EPS of $2.29.
PE Ratio
Gladstone Investment Corporation has a trailing twelve months price to earnings ratio of 6.44. Meaning, the purchaser of the share is investing $6.44 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.68%.
Yearly Top and Bottom Value
Gladstone Investment Corporation’s stock is valued at $14.74 at 19:22 EST, below its 52-week high of $14.96 and way above its 52-week low of $12.11.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is a negative 10% and positive 3.8% for the next.
Volume
Today’s last reported volume for Gladstone Investment Corporation is 101095 which is 49.35% below its average volume of 199632.
2. Medallion Financial Corp. (MFIN)
35.6% sales growth and 15.82% return on equity
Medallion Financial Corp., together with its subsidiaries, operates as a finance company in the United States. The company operates through four segments: Recreation Lending, Home Improvement Lending, Commercial Lending, and Medallion Lending. It provides loans that finance consumer purchases of recreational vehicles, boats, and trailers; consumer home improvements; commercial businesses; and taxi medallions to individuals, and small to mid-size businesses. The company also offers commercial loans for purchase of equipment and related assets necessary to open a new business, or purchase or improvement of an existing business; and medallion loans. In addition, it provides debt, mezzanine, and equity investment capital to companies in various industries; and raises deposits and conducts other banking activities. Medallion Financial Corp. was incorporated in 1995 and is headquartered in New York City, New York.
Earnings Per Share
As for profitability, Medallion Financial Corp. has a trailing twelve months EPS of $2.34.
PE Ratio
Medallion Financial Corp. has a trailing twelve months price to earnings ratio of 4.2. Meaning, the purchaser of the share is investing $4.2 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.82%.
Sales Growth
Medallion Financial Corp.’s sales growth is 14.5% for the ongoing quarter and 35.6% for the next.
Volume
Today’s last reported volume for Medallion Financial Corp. is 36750 which is 47.74% below its average volume of 70324.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is 10.5% and a drop 41.8% for the next.
Moving Average
Medallion Financial Corp.’s worth is above its 50-day moving average of $9.47 and way higher than its 200-day moving average of $7.95.
3. Neurocrine Biosciences (NBIX)
24.6% sales growth and 10.77% return on equity
Neurocrine Biosciences, Inc., a neuroscience-focused biopharmaceutical company, discovers, develops, and delivers various treatments for people with neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products also include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; NBI-827104 to treat rare pediatric epilepsy and other indications; and crinecerfont. The company's products in clinical development also comprise NBI-1065844 for the treatment of negative symptoms of schizophrenia; NBI-1065845 for the treatment of resistant depression; and NBI-1065846 for treating anhedonia in depression. It has license and collaboration agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; AbbVie Inc.; and Sentia Medical Sciences Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Neurocrine Biosciences has a trailing twelve months EPS of $1.9.
PE Ratio
Neurocrine Biosciences has a trailing twelve months price to earnings ratio of 73.56. Meaning, the purchaser of the share is investing $73.56 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.77%.
Volume
Today’s last reported volume for Neurocrine Biosciences is 1102700 which is 47.64% above its average volume of 746853.
Sales Growth
Neurocrine Biosciences’s sales growth is 26% for the ongoing quarter and 24.6% for the next.
Previous days news about Neurocrine Biosciences(NBIX)
- According to Zacks on Wednesday, 31 January, "Investors with an interest in Medical – Drugs stocks have likely encountered both Amylyx Pharmaceuticals, Inc. (AMLX Quick QuoteAMLX – Free Report) and Neurocrine Biosciences (NBIX Quick QuoteNBIX – Free Report) . ", "Right now, Amylyx Pharmaceuticals, Inc. is sporting a Zacks Rank of #2 (Buy), while Neurocrine Biosciences has a Zacks Rank of #3 (Hold). "
4. Semler Scientific (SMLR)
21.9% sales growth and 31.8% return on equity
Semler Scientific, Inc. develops, manufactures, and markets proprietary products that assist healthcare providers to evaluate and treat patients with chronic diseases in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition. Its products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, and family practitioners, as well as healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups. The company offers its products through salespersons and distributors. Semler Scientific, Inc. was incorporated in 2007 and is headquartered in Santa Clara, California.
Earnings Per Share
As for profitability, Semler Scientific has a trailing twelve months EPS of $2.5.
PE Ratio
Semler Scientific has a trailing twelve months price to earnings ratio of 18.34. Meaning, the purchaser of the share is investing $18.34 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 31.8%.
5. Employers Holdings (EIG)
5.9% sales growth and 13.01% return on equity
Employers Holdings, Inc., through its subsidiaries, operates in the commercial property and casualty insurance industry primarily in the United States. It offers workers' compensation insurance to small businesses in low to medium hazard industries. The company markets its products through independent local, regional, and national agents and brokers; alternative distribution channels; and national, regional, and local trade groups and associations, as well as directly to customers. Employers Holdings, Inc. was founded in 2000 and is based in Reno, Nevada.
Earnings Per Share
As for profitability, Employers Holdings has a trailing twelve months EPS of $4.41.
PE Ratio
Employers Holdings has a trailing twelve months price to earnings ratio of 9.45. Meaning, the purchaser of the share is investing $9.45 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.01%.
Previous days news about Employers Holdings(EIG)
- According to Zacks on Tuesday, 30 January, "Aflac Incorporated (AFL Quick QuoteAFL – Free Report) , Unum Group (UNM Quick QuoteUNM – Free Report) , Employers Holdings (EIG Quick QuoteEIG – Free Report) and Trupanion (TRUP Quick QuoteTRUP – Free Report) should continue to benefit from prudent underwriting standards. "
